Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  1. Lower or Higher Oxygenation Targets for Acute Hypoxemic Respiratory Failure

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Monoclonal Antibody for Patients with Covid-19. Reply

    Publikation: Bidrag til tidsskriftLetterpeer review

  3. A Neutralizing Monoclonal Antibody for Hospitalized Patients with Covid-19

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Baricitinib plus Remdesivir for Hospitalized Adults with Covid-19

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  5. Tocilizumab in Patients Hospitalized with Covid-19 Pneumonia

    Publikation: Bidrag til tidsskriftLetterpeer review

  1. Repeated Activation of Noradrenergic Receptors in the Ventromedial Hypothalamus Suppresses the Response to Hypoglycemia

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Effects of carbamazepine, eslicarbazepine, valproic acid and levetiracetam on bone microarchitecture in rats

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Semaglutide for the treatment of non-alcoholic steatohepatitis: Trial design and comparison of non-invasive biomarkers

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Detection of Hypoglycemia Using Measures of EEG Complexity in Type 1 Diabetes Patients

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  • Philip N Newsome
  • Kristine Buchholtz
  • Kenneth Cusi
  • Martin Linder
  • Takeshi Okanoue
  • Vlad Ratziu
  • Arun J Sanyal
  • Anne-Sophie Sejling
  • Stephen A Harrison
  • NN9931-4296 Investigators
Vis graf over relationer

BACKGROUND: Nonalcoholic steatohepatitis (NASH) is a common disease that is associated with increased morbidity and mortality, but treatment options are limited. The efficacy and safety of the glucagon-like peptide-1 receptor agonist semaglutide in patients with NASH is not known.

METHODS: We conducted a 72-week, double-blind phase 2 trial involving patients with biopsy-confirmed NASH and liver fibrosis of stage F1, F2, or F3. Patients were randomly assigned, in a 3:3:3:1:1:1 ratio, to receive once-daily subcutaneous semaglutide at a dose of 0.1, 0.2, or 0.4 mg or corresponding placebo. The primary end point was resolution of NASH with no worsening of fibrosis. The confirmatory secondary end point was an improvement of at least one fibrosis stage with no worsening of NASH. The analyses of these end points were performed only in patients with stage F2 or F3 fibrosis; other analyses were performed in all the patients.

RESULTS: In total, 320 patients (of whom 230 had stage F2 or F3 fibrosis) were randomly assigned to receive semaglutide at a dose of 0.1 mg (80 patients), 0.2 mg (78 patients), or 0.4 mg (82 patients) or to receive placebo (80 patients). The percentage of patients in whom NASH resolution was achieved with no worsening of fibrosis was 40% in the 0.1-mg group, 36% in the 0.2-mg group, 59% in the 0.4-mg group, and 17% in the placebo group (P<0.001 for semaglutide 0.4 mg vs. placebo). An improvement in fibrosis stage occurred in 43% of the patients in the 0.4-mg group and in 33% of the patients in the placebo group (P = 0.48). The mean percent weight loss was 13% in the 0.4-mg group and 1% in the placebo group. The incidence of nausea, constipation, and vomiting was higher in the 0.4-mg group than in the placebo group (nausea, 42% vs. 11%; constipation, 22% vs. 12%; and vomiting, 15% vs. 2%). Malignant neoplasms were reported in 3 patients who received semaglutide (1%) and in no patients who received placebo. Overall, neoplasms (benign, malignant, or unspecified) were reported in 15% of the patients in the semaglutide groups and in 8% in the placebo group; no pattern of occurrence in specific organs was observed.

CONCLUSIONS: This phase 2 trial involving patients with NASH showed that treatment with semaglutide resulted in a significantly higher percentage of patients with NASH resolution than placebo. However, the trial did not show a significant between-group difference in the percentage of patients with an improvement in fibrosis stage. (Funded by Novo Nordisk; ClinicalTrials.gov number, NCT02970942.).

OriginalsprogEngelsk
TidsskriftThe New England journal of medicine
Vol/bind384
Udgave nummer12
Sider (fra-til)1113-1124
Antal sider12
ISSN0028-4793
DOI
StatusUdgivet - 25 mar. 2021
Eksternt udgivetJa

Bibliografisk note

Copyright © 2020 Massachusetts Medical Society.

ID: 61735551